TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02108691

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glycin max(L.) Merr. peel extract
Description: Glycin max(L.) Merr. peel extract (2.5g/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (2.5g/day)
Study: NCT04147546

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Additional screening using ultra sensitive RDTs
Description: At each ANC visit, study nurses will perform an HS-RDT for participants in the intervention arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquin
Description: All pregnant women with a positive HS-RDT will be treated with a full course of dihydroartemisinin-piperaquine (DP) over 3 days. The first dose of DP will be administered under direct observation at the antenatal care clinic (ANC) and the subsequent doses of the intervention in days 2 and 3 will be taken unsupervised at home

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reminders
Description: Before each scheduled ANC visit, reminders using SMS or phone call will be used. This is order to increase ANC attendance
Study: NCT02858752

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experience 1 : Auditory and Visual Discrimination
Description: Neuropsychological tests consist in listening to sounds in various contexts and providing behavioral responses with response-buttons.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experience 2 : Passive and Active Auditory Perception
Description: Neuropsychological tests consist in listening to sounds under 2 conditions, an active or a passive one, during which different auditory stimuli will be presented: frequent stimuli (standard) and rare stimuli (deviants). These two stimuli differ in some of their feature (height, duration, ...). A third, very rare (novel) stimulus will also be used (the subject's first name). Responses will be provided using a response-button and feedback will be given at each response. EEG will be recorded all along to measure Neurophysiological signals.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experience 3 : Visual Attention Training
Description: This experience aims at training visual attention through serious games. Children will play against an artificial intelligence and will focus their attention on one out of many possible targets (checkers, cards, boxes) presented on screen. Responses will be provided using a response-button, sometimes completed by an eye-tracking measure. Feedback will be given to the child after his response. EEG will be recorded all along to measure Neurophysiological signals.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experience 4 : Attention and Distractibility
Description: Neuropsychological tests consist in listening to sounds preceded by a visual cue indicating (or not) in which ear the sounds will be played. The subject Child should detect the target sound (e.g. a dog barking). In some trials, a distracting distraction will be introduced between the visual cue and the target sound. Responses will be provided using a response-button. EEG will be recorded all along to measure Neurophysiological signals.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experience 5 : Sustained Visual Attention
Description: Neuropsychological tests consist in watching visual stimuli presented in 3 blocks of 3 minutes each, with a break of one minute between each block. The child has to detect the presence of a red letter in a pattern made of four letters (the three other letters are black). Behavioral responses will be provided using a response-button. EEG will be recorded all along to measure Neurophysiological signals.
Study: NCT00626405

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV over 30-90 minutes

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV over 30-90 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV over 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel albumin-stabilized nanoparticle formulation
Description: Given IV over 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Oral temozolomide on days 1-5
Study: NCT00951405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: activated recombinant human factor VII, long acting
Description: After an observation period of 3 months, every 2nd day intravenous (i.v.) injection with 25 microgrammes/kg activated recombinant human factor VII, long acting, for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: activated recombinant human factor VII, long acting
Description: After an observation period of 3 months, every 2nd day intravenous (i.v.) injection with 100 microgrammes/kg activated recombinant human factor VII, long acting, for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: activated recombinant human factor VII, long acting
Description: After an observation period of 3 months, every 2nd day intravenous (i.v.) injection with 200 microgrammes/kg activated recombinant human factor VII, long acting, for 3 months
Study: NCT02274545

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H7N9 Anhui 2013/AA ca
Description: 10\^7.0 fluorescent focus units (FFU); 0.5 mL of vaccine will be delivered as a nasal spray by an Accuspray device (0.25 mL per nostril)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated subvirion H7N9 vaccine
Description: 30 mcg
Study: NCT00709878

Intervention type: PROCEDURE
Intervention: Skin Biopsy of Skin Rash Secondary to EGFRI Use
Description: Patients who were treated with lapatinib, cetuximab, panitumumab or erlotinib who subsequently developed a skin rash have been biopsied as standard of care. The biopsies will be used for this study.

Intervention type: PROCEDURE
Intervention: Skin Biopsy of Skin Rash Secondary to EGFRI Use
Description: Patients who were treated with lapatinib, cetuximab, panitumumab or erlotinib who subsequently developed a skin rash have been biopsied as standard of care. The biopsies will be used for this study.

Intervention type: PROCEDURE
Intervention: Skin Biopsy of Skin Rash Secondary to EGFRI Use
Description: Patients who were treated with lapatinib, cetuximab, panitumumab or erlotinib who subsequently developed a skin rash have been biopsied as standard of care. The biopsies will be used for this study.

Intervention type: PROCEDURE
Intervention: Skin Biopsy of Skin Rash Secondary to EGFRI Use
Description: Patients who were treated with lapatinib, cetuximab, panitumumab or erlotinib who subsequently developed a skin rash have been biopsied as standard of care. The biopsies will be used for this study.
Study: NCT00081211

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PV701
Description: Given intratumorally
Study: NCT02107157

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 755nm Laser with Cap Array
Study: NCT02648672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPN14770
Description: BPN14770 is an investigational new drug being developed for the treatment of Alzheimer's disease and other cognitive disorders. BPN14770 is a small molecule, subtype selective, negative allosteric modulator of phosphodiesterase 4D.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02508324

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: haplo-identical cells (donor)
Description: Treatment: Haplo-identical healthy related donor. i.e. Parent, child, sibling, possibly third degree or further removed relative (cousin, aunt, nephew etc). They will be collected using standard methods and approximately 3 x10\^6 CD34 cells/kg will be infused within 72 hours after completion of the treatment.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: umbilical cord blood unit (CBU)
Description: Treatment: The CBU unit must supply a minimum of 0.5 x107/kg and a maximum of 2.5x107/kg nucleated cell dose pre-cryopreservation. The unit must match at a minimum of 4 of 6 at HLA-A, -B antigens, -DRB1 alleles with the recipient. Mismatches (0-2) can be at any loci -. Although molecular level typing will be available for the patient and the CBU unit, a match is defined at intermediate resolution for HLA-A and -B and at high resolution for -DRB1. The CBU donor will also have undergone HLA typing of the mother, thus allowing determination of the CBU-IPA and NIMA. CBU grafts used in this study will be investigational units that meet all criteria for clinical use. Better matching units will be preferred over less matching units as long as the CBU dose exceeds 0.5 x107 nucleated blood cells/kg
Study: NCT00123604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: 25 mg twice daily for five months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: 200 mg twice daily for five months.
Study: NCT03959787

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational
Description: Educational pamphlet will be given to intervention group.
Study: NCT02666105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: One 25 mg tablet once daily for a minimum of 6 weeks
Study: NCT02138357

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: buprenorphine transdermal delivery system (BTDS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine transdermal delivery system (BTDS)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for BTDS patch
Description: A placebo patch will be manufactured to mimic the BTDS patch.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for BTDS patch
Description: A placebo patch will be manufactured to mimic the BTDS patch.
Study: NCT04216355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Low-dose AZA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAG Protocol
Description: Short term CAG derived regimen
Study: NCT00351325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663513
Description: mg/kg, IV, 0.3, 1, 3, 10 mg/kg, q 3 wks, up to 24 weeks
Study: NCT00252616

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: trophic enteral feeds
Description: 10cc/hr

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: trophic enteral feeds
Description: 10cc/hr
Study: NCT02687516

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-based behavioral social facilitation therapy
Description: Family-based Behavioral Social Facilitation Treatment (FBSFT) is founded on the principles of standard family-based behavioural therapy for obesity. FBSFT targets life-style behaviors (diet, physical activity and sedentary activity) in a family setting. FBSFT includes some cognitive elements that are considered important in relation to behavioural change for instance problem solving and cognitive restructuring. FBSFT has an intensive treatment phase including weekly family meetings with therapists over 17 consecutive weeks. Further monthly or bi-weekly follow-up sessions with a focus on social facilitation and maintenance of healthy habits are recommended. The dietary guidance of FBSFT is based on the Traffic light diet in which foods are organized into GREEN, YELLOW and RED groups. Activity guidance of FBSFT uses the same system: GREEN activities have the highest intensity and should be engaged in most often, YELLOW activities sometimes, and RED activities.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU - Treatment as usual
Description: This is the default treatment at the obesity clinic. After initial evaluation by paediatrician, nurse, nutritionist and physiotherapist, a contract is written including weight goal, nutritional plan and activity plan. Follow up monthly in primary Health care and every 3rd month at the obesity clinic.
Study: NCT04171232

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balance It
Description: Each patient in group 1 i.e. Balance It group would be given a 15 minutes long session. Each session would start in standing position and the patient would play the game while they would be instructed to balance the objects falling from above on the imaginary bar (and an actual bar at later stages) held with their both hands, and not let those objects fall by opening their arms wide open and by staying or moving according to the target spot for the set time. This session would be repeated three times a week for two months (total 12 sessions/month).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bubble Pop
Description: Each patient in group II i.e. Bubble Pop group would be given a 15 minutes long session. Each session would start in standing position and the patient would play the game while they would be instructed to reach for the balloons coming from random directions and pop them by moving their upper limbs and even their whole body if required. They would also be instructed to avoid a specific object that would result in deduction of their overall game score. This session would be repeated three times a week for two months (total 12 sessions/month).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Scoop'd
Description: Each patient in group III i.e. Scoop'd group would be given a 15 minutes long session. Each session would start in standing position and the patient would play the game while they would be instructed to hold an imaginary ice cream cone (and an actual basket designed similar to an ice cream cone in later stages) with their both hands and move to catch the ice cream scoops falling at random spots from above, one spot at a time. They would also be instructed to avoid a specific object that would result in deduction of their overall game score. This session would be repeated three times a week for two months (total 12 sessions/month).
Study: NCT04088526

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: intervention group
Description: Through effective intervention combined with drugs and dietary guidance within 3 to 6 months, all the observation markers including blood pressure and laboratory results will reach the target target value.
Study: NCT03834935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elidel (pimecrolimus 1%)
Description: topical application of product on all lesions, twice daily. Sunscreen will not be indicated, and hygienic habits will not be changed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cold Cream
Description: Topical application on all lesions, twice daily. Sunscreen will not be indicated, and hygienic habits will not be changed
Study: NCT01384032

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low fat diet
Description: Subjects were asked to consume a low fat diet for 8 weeks. Composition: 28% energy from fat, 8% energy from saturated fat, 55% energy from carbohydrate. Subjects were provided with low fat spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume two extra portions of carbohydrate per day (e.g. two slices of bread, equivalent to 35g carbohydrate) and to consume low fat dairy products. Subjects also consumed 2g control oil per day during this period. Control oil comprised palm olein and soybean oil.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hgih saturated fat diet
Description: Subjects were asked to consume a high saturated fat diet for 8 weeks. Composition: 38% energy from fat, 18% energy from saturated fat, 45% energy from carbohydrate. Subjects were provided with spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume one less portion of carbohydrate per day (e.g. one slice of bread and to consume full fat dairy products. Subjects also consumed 2g control oil per day during this period. Control oil comprised palm olein and soybean oil.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High saturated fat diet
Description: Subjects were asked to consume a high saturated fat diet for 8 weeks. Composition: 38% energy from fat, 18% energy from saturated fat, 45% energy from carbohydrate. Subjects were provided with spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume one less portion of carbohydrate per day (e.g. one slice of bread and to consume full fat dairy products. Subjects also consumed 6g DHA-rich oil per day during this period providing 3g DHA.
Study: NCT00523250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-102 0.005% Ophthalmic Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-102 0.01% Ophthalmic Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-102 0.03% Ophthalmic Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-102 Vehicle Ophthalmic Solution
Study: NCT00003147

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad5CMV-p53 gene
Study: NCT02424383

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTA (Lutonix® 035 DCB Catheter)
Description: Percutaneous Transluminal Angioplasty (PTA) will involve the insertion of a catheter into one of the femoral arteries. Once the catheter is in place, a tiny balloon on the end of the catheter will be inflated to press against the narrowing (or blockage) in the artery to try to open the blockage, and allow more blood to flow through the artery. The balloon may need to be inflated several times in order for the narrowed area to open up sufficiently to improve the blood flow. The area will be viewed with specialized x-ray or other imaging devices to see if the artery has opened enough.~The Lutonix® DCB through the blood vessel to the narrowed area to be treated.
Study: NCT02308410

Intervention type: PROCEDURE
Intervention: Tourniquet application during surgery
Description: Both groups received usual care according to the orthopedic surgeons surgical preferences. One group received no tourniquet during surgery (non-tourniquet group) and the other group received a pneumatic tourniquet during surgery (tourniquet-group).
Study: NCT00003573

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT00664326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: Patients will be treated with BAY73-4506 160 mg po qd for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off). Patients will continue treatment with BAY73-4506 until disease progression, intolerable toxicity, or patient refusal to continue with the study or investigator decision to remove the patient from study.
Study: NCT04512508

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Self test sample
Description: Self test sample, DNA analysis, Biopsy and Anoscopy

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Self test sample
Description: Self test sample, DNA analysis, Biopsy and Anoscopy
Study: NCT02967939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-2802
Description: DA-2802 319mg tablet qd + placebo tablet matching to Viread® 300mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Viread®
Description: Viread® 300mg tablet qd + placebo tablet matching to DA-2802 319mg.
Study: NCT03042260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim-Sulfamethoxazole
Description: oral tablets, 3 times a week, for a minimum of 6 months and maximum of 1 year.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: oral tablets, 3 times a week, for a minimum of 6 months and maximum of 1 year.
Study: NCT01820052

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Iron
Description: 230 mg of elemental oral iron tablets will be administered daily for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Placebo
Description: Oral tablets matching oral iron will be administered daily for 3 months
Study: NCT05757674

Intervention type: OTHER
Intervention: Sample examination
Description: No intervention will be performed
Study: NCT01825941

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoclopramide
Description: 10 milligrams, administered intravenously over 15 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: metoclopramide
Description: 10 milligrams, administered intravenously over 15 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: diphenhydramine
Description: 50 milligrams, administered intravenously over 15 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00842504

Intervention type: DRUG
Group type: OTHER
Intervention: Micafungin
Description: 3 mg/kg IV once over 1 hour
Study: NCT02134912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizotinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03778684

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Visceral fat thickness
Description: An initial longitudinal sweep will be done from the xiphoid process to the umbilicus to determine the area of maximum pre-peritoneal fat thickness.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Visceral fat thickness
Description: An initial longitudinal sweep will be done from the xiphoid process to the umbilicus to determine the area of maximum pre-peritoneal fat thickness.
Study: NCT02869698

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spectral Dynamic Imaging

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybride electrode

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Macro electrode
Study: NCT02191605

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eSBIRT
Description: A single 20 minute interactive computer-delivered intervention designed to promote motivation to change prenatal marijuana use, without presuming the participant to be currently using marijuana while pregnant.